Polypharmacy in psychiatry is common, and the difference between rational combinations and irrational accumulation is one of the more important distinctions in modern prescribing. The patient with 8-12 psychiatric medications may be receiving excellent care or may be the victim of clinical drift; the chart usually tells the story.
- Class
- Polypharmacy decision framework
- Mechanism
- Rational combinations target complementary mechanisms; irrational polypharmacy adds risk without proportional benefit
- FDA indications
- Treatment-resistant cases, comorbid conditions, augmentation strategies
Evidence-supported combinations: SSRI + bupropion (mood + sexual dysfunction); SSRI + mirtazapine ("California Rocket Fuel"); mood stabilizer + antipsychotic (severe mania); stimulant + alpha-2 agonist (ADHD coverage); donepezil + memantine (Alzheimer's); buprenorphine + naloxone (OUD with abuse deterrence). Question for every added medication: what mechanism is added, what risk is added, what monitoring needed.
Rational combinations target complementary mechanisms with monitored benefit. Examples: SSRI plus bupropion (mood plus sexual dysfunction reversal). SSRI plus mirtazapine — "California Rocket Fuel" for treatment-resistant depression. Mood stabilizer plus atypical antipsychotic for severe mania. Donepezil plus memantine for Alzheimer's. Stimulant plus alpha-2 agonist for ADHD with hyperactivity. Each combination has a clinical rationale, established evidence, and a clear story for what each component contributes.
Rational polypharmacy combines agents whose mechanisms are complementary — the discipline is ensuring each drug has a defined, distinct purpose.
Mechanism note: Rational polypharmacy combines complementary mechanisms with a defined purpose for each agent; redundant or unexamined polypharmacy adds toxicity without benefit — audit the regimen regularly.
Irrational polypharmacy is the pattern where medications accumulate over years without ever being subtracted. Three antidepressants, two antipsychotics, two benzodiazepines — each added at a moment when the patient was struggling, each retained because removing it might cause problems. The cumulative side effect burden becomes substantial. Drug interactions multiply. Adherence becomes complex. The patient's overall well-being often declines despite (or because of) the expanding regimen.
The diagnostic question at every visit with a polypharmacy patient: what does each medication do, and is it still doing it? Some medications were added for a specific clinical situation that has resolved. Some never produced clear benefit. Some are duplicative with other agents on the list. Naming each medication's role — and identifying those whose role is unclear — is the first step toward rationalization.
Deprescribing is its own clinical skill. Systematic medication review. Identification of candidates for tapering. Engagement with patient and family — they need to understand why and what to expect. Gradual taper, one medication at a time. Monitor for symptom recurrence vs. withdrawal effects. Reassess at intervals. Many polypharmacy patients experience substantial functional improvement when their regimen is simplified.
Avoid the reflexive add-without-subtract pattern. Ask, at every visit: which medications are working, which aren't, which could be tapered.